Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

[1]  Jean Bennett,et al.  Novel mobility test to assess functional vision in patients with inherited retinal dystrophies , 2018, Clinical & experimental ophthalmology.

[2]  Jean Bennett,et al.  Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.

[3]  David J. Wilson,et al.  Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. , 2016, Ophthalmology.

[4]  Ava K. Bittner,et al.  Safety and Proof-of-Concept Study of Oral QLT091001 in Retinitis Pigmentosa Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) , 2015, PloS one.

[5]  B. Lorenz,et al.  Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark , 2015, European Journal of Human Genetics.

[6]  Kathleen A. Marshall,et al.  Plasticity of the human visual system after retinal gene therapy in patients with Leber’s congenital amaurosis , 2015, Science Translational Medicine.

[7]  A. J. Roman,et al.  Improvement and decline in vision with gene therapy in childhood blindness. , 2015, The New England journal of medicine.

[8]  S. E. Barker,et al.  Long-term effect of gene therapy on Leber's congenital amaurosis. , 2015, The New England journal of medicine.

[9]  A. Auricchio,et al.  Vector platforms for gene therapy of inherited retinopathies , 2014, Progress in Retinal and Eye Research.

[10]  Gislin Dagnelie,et al.  Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial , 2014, The Lancet.

[11]  Gislin Dagnelie,et al.  A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients , 2014, Clinical & experimental optometry.

[12]  K. High,et al.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy. , 2013, Blood.

[13]  Paolo Melillo,et al.  Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. , 2013, Ophthalmology.

[14]  Alexander Sumaroka,et al.  Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement , 2013, Proceedings of the National Academy of Sciences.

[15]  Jian-xing Ma,et al.  RPE65 Is Present in Human Green/Red Cones and Promotes Photopigment Regeneration in an In Vitro Cone Cell Model , 2011, The Journal of Neuroscience.

[16]  Michael J. Castle,et al.  Dosage Thresholds for AAV2 and AAV8 Photoreceptor Gene Therapy in Monkey , 2011, Science Translational Medicine.

[17]  Kathleen A. Marshall,et al.  The human visual cortex responds to gene therapy-mediated recovery of retinal function. , 2011, The Journal of clinical investigation.

[18]  J. F. Wright,et al.  Manufacturing and regulatory strategies for clinical AAV2-hRPE65. , 2010, Current gene therapy.

[19]  Jean Bennett,et al.  Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Kathleen A. Marshall,et al.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial , 2009, The Lancet.

[21]  D. Birch,et al.  Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST) , 2009, Documenta Ophthalmologica.

[22]  J. F. Wright,et al.  Transient transfection methods for clinical adeno-associated viral vector production. , 2009, Human gene therapy.

[23]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[24]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[25]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[26]  J. F. Wright,et al.  Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  W. Hauswirth,et al.  Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  T Michael Redmond,et al.  Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. F. Wright,et al.  Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  Ying Chen,et al.  Identification of RDH10, an All-trans Retinol Dehydrogenase, in Retinal Muller Cells. , 2004, Investigative ophthalmology & visual science.

[31]  T. Aleman,et al.  In utero gene therapy rescues vision in a murine model of congenital blindness. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  J. Holladay,et al.  Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.

[33]  Jian-xing Ma,et al.  Identification of the RPE65 protein in mammalian cone photoreceptors. , 2002, Investigative ophthalmology & visual science.

[34]  Jean Bennett,et al.  Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.

[35]  P. Sieving,et al.  Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration. , 2000, Investigative ophthalmology & visual science.

[36]  D. Bok,et al.  Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle , 1998, Nature Genetics.

[37]  A. Fulton,et al.  Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Hendrickson,et al.  Human photoreceptor topography , 1990, The Journal of comparative neurology.

[39]  A. D. den Hollander.  Omics in Ophthalmology: Advances in Genomics and Precision Medicine for Leber Congenital Amaurosis and Age-Related Macular Degeneration. , 2016, Investigative Ophthalmology and Visual Science.

[40]  M. Kono.  Cone Health and Retinoids. , 2015, Progress in molecular biology and translational science.

[41]  M. Bach,et al.  Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT) , 2008, Graefe's Archive for Clinical and Experimental Ophthalmology.

[42]  A. Wenzel,et al.  Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA. , 2006, Advances in experimental medicine and biology.